FDA Accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

HOOKIPA Pharma, Inc. received US FDA acceptance of its Investigational New Drug application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.